Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Phase 2 Recruiting
165 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Phase 2 Recruiting
80 enrolled
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2 Recruiting
377 enrolled
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase 2 Recruiting
140 enrolled
N-Plus
Phase 2 Recruiting
640 enrolled
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Phase 2 Recruiting
43 enrolled
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Phase 2 Recruiting
86 enrolled
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Phase 2 Recruiting
110 enrolled
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Phase 2 Recruiting
230 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Phase 2 Recruiting
18 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Phase 2 Recruiting
32 enrolled
PRESELECT-0
Phase 2 Recruiting
18 enrolled
Preselect-1
Phase 2 Recruiting
126 enrolled
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Phase 2 Recruiting
33 enrolled
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Phase 2 Recruiting
60 enrolled
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Phase 2 Recruiting
220 enrolled
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2 Recruiting
460 enrolled
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Phase 2 Recruiting
54 enrolled
ACTOv
Phase 2 Recruiting
80 enrolled
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
Phase 2 Recruiting
75 enrolled